Cargando…

A46 BIOGEOGRAPHIC VARIATION AND FUNCTIONAL PATHWAYS OF THE GUT MICROBIOTA IN CELIAC DISEASE

BACKGROUND: Genes and gluten are necessary, but insufficient to cause celiac disease (CeD), as risk alleles (DQ2 or DQ8) are prevalent in ~30–40% of the healthy population consuming gluten. Gut microbiota shifts and infections have been proposed as risk modulators. Biogeographic characterization of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Libertucci, J, Constante, M, Galipeau, H J, Szamosi, J C, Rueda, G H, Pinto-Sanchez, M I, Southward, C M, Rossi, L M, Fontes, M E, Chirdo, F G, Surette, M, Bercik, P, CAMINERO FERNANDEZ, A, Verdu, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Poster of Distinction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859172/ http://dx.doi.org/10.1093/jcag/gwab049.045

Ejemplares similares

A144 CHRONIC DSS LEADS TO ALTERED EXPRESSION OF IRAK4/TPL2 PATHWAYS IN UC-COLONIZED MICE
por: Hann, A, et al.
Publicado: (2022)

A248 THE ROLE OF DIETARY TRYPTOPHAN IN INDOLE AND KYNURENINE PRODUCTION AND IMMUNE MODULATION IN HEALTHY INDIVIDUALS
por: Rueda, G H, et al.
Publicado: (2022)

A45 FIBER-FREE DIET REDUCES BACTEROIDES ABUNDANCE AND PREVENTS MUCUS DEGRADATION IN MICE COLONIZED WITH MICROBIOTA FROM PATIENTS WITH GENERALIZED ANXIETY DISORDER
por: Rabbia, V, et al.
Publicado: (2023)

A34 GLUTEN-FREE DIET IMPROVES DYSPEPTIC SYMPTOMS IN PATIENTS WITH TYPE 1 DIABETES IN WHOM CELIAC DISEASE WAS EXCLUDED
por: Miranda, P M, et al.
Publicado: (2022)

A3 CROHN’S DISEASE PROTEOLYTIC MICROBIOTA ENHANCES INFLAMMATION THROUGH PAR2 PATHWAY IN GNOTOBIOTIC MICE
por: Hann, A, et al.
Publicado: (2023)

A192 CONSUMPTION OF FOOD LOWER IN TRYPTOPHAN IS ASSOCIATED WITH SIGNIFICANT ANXIETY IN PATIENTS WITH CELIAC DISEASE
por: Gupta, V, et al.
Publicado: (2022)

A53 FECAL BIOACTIVE PHOSPHOLIPIDS AS TRIGGERS OF INTESTINAL HYPERSENSITIVITY IN IRRITABLE BOWEL SYNDROME
por: Pujo, J, et al.
Publicado: (2023)

A194 THE ADDITION OF DEAMIDATED GLIADIN PEPTIDE TO TISSUE TRANSGLUTAMINASE ANTIBODIES DOES NOT INCREASE THE ODDS OF CELIAC DISEASE DIAGNOSIS IN AN IGA SUFFICIENT POPULATION
por: Moss, K, et al.
Publicado: (2022)

A32 PHAGE TREATMENT DELAYS ONSET OF CROHN’S-ASSOCIATED E. COLI DRIVEN COLITIS IN MICE COLONIZED WITH A DEFINED MICROBIOTA
por: Jackson, K, et al.
Publicado: (2023)

A46 ENTEROBACTERIACEAE ENRICHMENT IN THE GUT MICROBIOME OF CRITICALLY ILL PATIENTS PROMOTES IMMUNE DYSFUNCTION AND SUSCEPTIBILITY TO NOSOCOMIAL INFECTIONS
por: Schlechte, J M, et al.
Publicado: (2023)

Crohn’s disease proteolytic microbiota enhances inflammation through PAR2 pathway in gnotobiotic mice
por: Santiago, Alba, et al.
Publicado: (2023)

A51 ROLE OF GUT MICROBIOTA IN THE EPISODIC NATURE OF SYMPTOMS IN IRRITABLE BOWEL SYNDROME
por: Mohan, V, et al.
Publicado: (2022)

Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2
por: Caminero, Alberto, et al.
Publicado: (2019)

A33 EFFECTS OF THE NEXT GENERATION PROBIOTIC, AKKERMANSIA MUCINIPHILA, ON INTESTINAL INFLAMMATION AND BARRIER FUNCTION
por: Grondin, J, et al.
Publicado: (2023)

A233 CHARACTERIZATION OF THE DUODENAL MICROBIOME IN PEDIATRIC CELIAC AND INFLAMMATORY BOWEL DISEASE PATIENTS
por: Manoogian, J, et al.
Publicado: (2022)

A48 OPTIMIZATION OF TRYPTOPHAN-CONTAINING DIETS TO ACTIVATE THE ARYL HYDROCARBON RECEPTOR AND REDUCE SUSCEPTIBILITY TO COLITIS
por: Rondeau, L, et al.
Publicado: (2022)

A51 INTESTINAL MICROBIOTA DETERMINES ARYL HYDROCARBON RECEPTOR ACTIVATION AND SUSCEPTIBILITY TO COLITIS
por: Rondeau, L, et al.
Publicado: (2023)

A191 PERSISTENT BENEFIT OF DIETITIAN-LED GLUTEN-FREE DIET EDUCATION AT CD DIAGNOSIS ON DIETARY ADHERENCE IN CHILDREN AND ADULTS WITH TYPE 1 DIABETES AND CELIAC DISEASE
por: Marcon, P, et al.
Publicado: (2022)

A67 ABC, EASY AS 123, SIMPLE AS GLUTEN-FREE? KNOWLEDGE AND ADHERENCE IN ADOLESCENTS WITH CELIAC DISEASE
por: Pohoreski, K, et al.
Publicado: (2022)

A7 OPPORTUNISTIC PATHOGEN MODULATION OF GLUTEN-REACTIVE CD4+ T CELL ACTIVATION BY DQ2-EXPRESSING ORGANOID MONOLAYERS
por: Rahmani, S, et al.
Publicado: (2023)

A44 A 1000 PATIENT CANADIAN NETWORK FOR AUTOIMMUNE LIVER DISEASE EVALUATION OF CLINICAL AND DEMOGRAPHIC PATTERNS OF AUTOIMMUNE HEPATITIS
por: Plagiannakos, C G, et al.
Publicado: (2023)

A173 INNOVATIVE CARE FOR INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: USE OF BEDSIDE INTESTINAL ULTRASOUND TO OPTIMIZE MANAGEMENT
por: Novak, K L, et al.
Publicado: (2021)

A208 ASSESSING FEASIBILITY AND ACCEPTABILITY OF AN ONLINE MIND-BODY WELLNESS PROGRAM FOR PRIMARY BILIARY CHOLANGITIS
por: Watt, M, et al.
Publicado: (2022)

A217 TREATMENT ADHERENCE OF CHRONIC HEPATITIS B PATIENTS WITH HEPATOCELLULAR CARCINOMA FROM THE CANHEPB NETWORK
por: Rahman, S H, et al.
Publicado: (2022)

A183 SUCCINATE IN THE RELATIONSHIP BETWEEN INFLAMMATORY BOWEL DISEASE AND OBESITY IN SUCCINATE RECEPTOR DEFICIENT MICE
por: Arsenault, A M, et al.
Publicado: (2022)

A66 THE IMPACT OF A MULTIDISCIPLINARY ADOLESCENT AND YOUNG ADULT (AYA) INFLAMMATORY BOWEL DISEASE (IBD) ON CLINIC NO SHOW RATES
por: Sharma, R, et al.
Publicado: (2022)

A224 COVID-19 INFECTION IN LIVER TRANSPLANT RECIPIENTS: CLINICAL FEATURES, HOSPITALIZATION, AND MORTALITY FROM A CANADIAN MULTICENTRE COHORT
por: Smith, M K, et al.
Publicado: (2022)

A133 EVALUATION OF DYSPHAGIA IN AN ACADEMIC CENTRE
por: Reed, D E, et al.
Publicado: (2022)

A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
por: Cooper, J, et al.
Publicado: (2022)

A202 IMPACT OF THE COVID-19 PANDEMIC ON THE EPIDEMIOLOGY OF ALCOHOL-RELATED HEPATITIS
por: Frolkis, A, et al.
Publicado: (2022)

A80 CANADIAN NEUROGASTROENTEROLOGY NETWORK (CNN) SURVEY ON PH/MOTILITY TESTING IN CANADA
por: Reed, D E, et al.
Publicado: (2022)

A47 THE GUT MICROBIOTA INFLUENCES COLONIC HEALING AFTER SURGERY IN PATIENTS UNDERGOING BOWEL RESECTION FOR COLORECTAL CANCER
por: Hajjar, R, et al.
Publicado: (2023)

A26 DECONSTRUCTING DISTRESS: STAKEHOLDER ENGAGEMENT FOR EVIDENCE-BASED, PATIENT-CENTERED INTERVENTIONS FOR THE MANAGEMENT OF IBD-ASSOCIATED PSYCHOLOGICAL DISTRESS
por: Heisler, C, et al.
Publicado: (2022)

A50 THE EFFECTS OF SHORT-CHAIN FATTY ACIDS ON EPITHELIAL AND MACROPHAGE RESPONSE TO BACTEROIDES FRAGILIS
por: Bording-Jorgensen, M, et al.
Publicado: (2023)

A96 RAPID IMPLEMENTATION OF AN EVIDENCE-BASED, VIRTUAL COVID-19 VACCINE EDUCATION CLINIC AT NOVA SCOTIA COLLABORATIVE INFLAMMATORY DISEASE CLINIC (NSCIBD)
por: Komeylian, H, et al.
Publicado: (2022)

A47 MICROBIAL FUNCTIONS AS BIOMARKERS OF PRO-INFLAMMATORY RESPONSE TO SELECT DIETARY FIBERS IN IBD
por: Armstrong, H, et al.
Publicado: (2022)

A141 IS SURGERY STILL THE ONLY TREATMENT OPTION FOR CURABLE RECTAL CANCER?
por: Vuong, T, et al.
Publicado: (2022)

A236 ASSOCIATION OF STOOL METABOLOMIC PROFILE AND MICROBIOME COMPOSITION RISK SCORE WITH FUTURE ONSET OF CROHN’S DISEASE
por: Lee, S, et al.
Publicado: (2022)

A78 “CHALLENGING PERSPECTIVES:” UNDERSTANDING CLINICIANS VIEWS ON MANAGING ALCOHOL USE DISORDER AND CIRRHOSIS
por: Johnson, E, et al.
Publicado: (2022)

A88 UNDERSTANDING NURSE PERCEPTIONS OF CARING FOR PATIENTS WITH ALCOHOL USE DISORDER: A CROSS-SECTIONAL STUDY
por: Hyde, A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pmu4r4vqft2v4ku2c5snil8vj8